Unusual Presentation of an Uncommon Malignancy: A 74-Year-Old Woman with Aggressive Fibromatosis of the Large Intestine Presenting as a Liver Mass and the Therapeutic Management.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
09 Oct 2023
09 Oct 2023
Historique:
medline:
23
10
2023
pubmed:
9
10
2023
entrez:
9
10
2023
Statut:
epublish
Résumé
BACKGROUND Desmoid tumors are a fibroblastic proliferation of soft tissues, with an extreme inclination for local dissemination and recurrence. Surgical excision is the usual treatment choice, with data regarding pharmaceutical treatment being scarce. CASE REPORT A 74-year-old female patient was admitted to "Laikon" General Hospital of Athens, Greece presenting with acute kidney injury secondary to diarrhea. The ultrasound, CT, and abdominal MRI performed showed a 12×6×10 cm tumorous liver lesion. Biopsy of the lesion revealed loosely organized, mesenchymal tissue with spindle cells, and myxoid stroma. Immunochemistry was positive for SMA and b-catenin. Right hemicolectomy was performed with tumor-free surgical margins (R0 resection) and tamoxifen was initiated. Six months after the last MRI (3 months after the use of tamoxifen), a follow-up MRI was performed. The tumor had increased to 14.2×11×12.3 cm, and at the next follow-up it had grown to 20.3×19 cm maximal dimensions; no new metastases were found. The patient received sorafenib and pazopanib. Our patient had PFS with sorafenib for more than 2 years and remained in a good performance status (ECOG 1). For Pazopanid, the median PFS for this treatment option was 6.5 months. CONCLUSIONS The results were good and show a promising method for the treatment of this rare but severe malignancy.
Identifiants
pubmed: 37812585
pii: 939862
doi: 10.12659/AJCR.939862
pmc: PMC10578500
doi:
Substances chimiques
Sorafenib
9ZOQ3TZI87
Tamoxifen
094ZI81Y45
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e939862Références
Diagn Interv Imaging. 2019 Jan;100(1):47-55
pubmed: 30037746
Int Orthop. 2004 Aug;28(4):252-6
pubmed: 15168085
Eur J Cancer. 2016 May;58:90-6
pubmed: 26974708
Cancer. 2010 May 1;116(9):2258-65
pubmed: 20187095
Oncol Lett. 2021 Jan;21(1):43
pubmed: 33262835
Ann Oncol. 2003 Feb;14(2):181-90
pubmed: 12562642
Eur J Cancer. 2017 May;76:60-67
pubmed: 28282612
N Engl J Med. 2018 Dec 20;379(25):2417-2428
pubmed: 30575484
Cancer. 2022 Aug 15;128(16):3027-3040
pubmed: 35670122
Oncologist. 2011;16(5):682-93
pubmed: 21478276
Pediatr Blood Cancer. 2018 Jun;65(6):e26968
pubmed: 29384266
Pathol Oncol Res. 2015 Sep;21(4):1085-90
pubmed: 25916970
Clin Cancer Res. 2010 Oct 1;16(19):4884-91
pubmed: 20724445
Lancet Oncol. 2019 Sep;20(9):1263-1272
pubmed: 31331699
Eur J Radiol. 2021 Jan;134:109406
pubmed: 33254066
Cancer. 2004 Feb 1;100(3):612-20
pubmed: 14745880
Allergy Asthma Proc. 2019 Nov 1;40(6):429-432
pubmed: 31690387
Cancers (Basel). 2020 Jul 09;12(7):
pubmed: 32660036
Eur J Cancer. 2020 Mar;127:96-107
pubmed: 32004793
Clin Exp Allergy. 2021 Jul;51(7):902-914
pubmed: 34080735
Ann Oncol. 2017 Oct 1;28(10):2399-2408
pubmed: 28961825
N Engl J Med. 2017 Jun 29;376(26):2595-2597
pubmed: 28657872
Rofo. 2020 May;192(5):448-457
pubmed: 31622987
J Natl Compr Canc Netw. 2016 Jun;14(6):758-86
pubmed: 27283169
J Clin Oncol. 2006 Jan 1;24(1):102-5
pubmed: 16382119
Cancer J. 2017 Mar/Apr;23(2):86-91
pubmed: 28410293